ID7 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
HST Outperformance & BacklogSustained double-digit orders and revenue growth in the Health & Science Technologies platform, plus a 100bp EBITDA margin lift and an expanding backlog, signal durable end-market demand (data centers, semiconductors, pharma). This provides multi-quarter visibility and supports above-company organic growth over time.
Strong Liquidity & Capital AllocationLarge liquidity reserves, moderate gross leverage (~2x) and disciplined buybacks plus steady dividends create financial optionality for bolt-on M&A and cyclical buffering. This capital flexibility supports long-term strategic execution and shareholder returns without materially stressing the balance sheet.
Consolidated Margin ExpansionYear-over-year EBITDA margin improvement indicates effective cost discipline and pricing power across the diversified portfolio. If sustained, these structural productivity gains and pricing actions can improve earnings resiliency through cycles and fund reinvestment or M&A without eroding returns.
Bears Say
Volatile Free Cash FlowDespite strong cash conversion in typical periods, the large TTM FCF drop signals material volatility tied to working capital or investment timing. This undermines predictability for capex, acquisitions and buybacks, raising the risk that funding patterns or returns fluctuate materially across reporting periods.
Life Sciences End-market PressureWeakness in life-science demand, especially from China and constrained public funding, can permanently pressure higher-margin product mix in HST and adjacent segments. Prolonged softness would limit margin expansion potential and slow the pace at which acquired businesses can be accretive to overall profitability.
Incremental Margin & Mix HeadwindsAcquisition-driven mix shifts and lower-margin add-ons reduce incremental flow-through, meaning revenue gains translate less efficiently into EBITDA. This structural drag requires 8020 portfolio actions to restore higher incremental margins and could delay margin targets while integration and portfolio optimization proceed.
IDEX News
ID7 FAQ
What was Idex Corporation’s price range in the past 12 months?
Currently, no data Available
What is Idex Corporation’s market cap?
Idex Corporation’s market cap is CHF13.49B.
When is Idex Corporation’s upcoming earnings report date?
Idex Corporation’s upcoming earnings report date is Jul 29, 2026 which is in 5 days.
How were Idex Corporation’s earnings last quarter?
Idex Corporation released its earnings results on Apr 29, 2026. The company reported $1.633 earnings per share for the quarter, beating the consensus estimate of $1.445 by $0.189.
Is Idex Corporation overvalued?
According to Wall Street analysts Idex Corporation’s price is currently Undervalued.
Does Idex Corporation pay dividends?
Idex Corporation does not currently pay dividends.
What is Idex Corporation’s EPS estimate?
Idex Corporation’s EPS estimate is 1.72.
How many shares outstanding does Idex Corporation have?
Currently, no data Available
What happened to Idex Corporation’s price movement after its last earnings report?
Idex Corporation reported an EPS of $1.633 in its last earnings report, beating expectations of $1.445. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Idex Corporation?
Currently, no hedge funds are holding shares in CH:ID7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IDEX Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF203.09 (― Downside)
CHF203.09 (― Downside)
Insider Transactions
Sold Shares
Worth CHF2.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.82%
Trailing 12-Months
Company Description
Idex Corporation
IDEX Corporation is an international enterprise specializing in engineered solutions across diverse sectors. The company operates through three primary business units: Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP). The FMT division is responsible for the design, production, and distribution of a range of fluid-handling equipment, including positive displacement pumps, flow meters, and injectors, alongside offering flow monitoring and related services. Its applications span the food, chemical, general industrial, water management, agricultural, and energy industries. Under the HST umbrella, IDEX develops and supplies precision components and systems for health and scientific applications. This includes advanced fluidic devices, various types of pumps (rotary lobe, centrifugal, positive displacement), roll compaction and drying technologies, pneumatic components, and sealing solutions, as well as biocompatible medical devices, optical components, and precision photonic solutions. Key markets for this segment encompass food and beverage, pharmaceutical, cosmetics, marine, chemical, wastewater treatment, life sciences, research, and defense. Finally, the FSDP segment delivers critical equipment for emergency services, such as firefighting pumps, valves, rescue tools, and lifting bags. It also provides engineered stainless steel banding and clamping devices for industrial and commercial use, alongside specialized precision equipment for dispensing, metering, and mixing colorants and paints for retail and commercial clients. IDEX Corporation was founded in 1987 and maintains its headquarters in Northbrook, Illinois.
ID7 Net sales Breakdown
35.36% Fluid & Metering Technologies
43.11% Health & Science Technologies
21.53% Fire & Safety/Diversified Products
ID7 Stock 12 Month Forecast
Average Price Target
$203.09